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Prior publications on small subsets of cancer patients infected with SARS CoV-2 have shown an increased
risk of mortality compared to the general population. Furthermore, patients with thoracic malignancies are
thought to be at particularly high risk given their older age, smoking habits, and pre-existing cardio-pulmo-
nary comorbidities. For this reason, physicians around the world have formed TERAVOLT, a global con-
sortium dedicated to understanding the impact of COVID-19 on patients with thoracic malignancies.Background
Coronavirus disease 2019 (COVID-19),
a respiratory tract infection caused by
the severe acute respiratory syndrome
(SARS) coronavirus (CoV), also named
SARS-CoV-2, began in Wuhan, China,
in 2019 followed by a rapid global spread
that led the World Health Organization to
declare a pandemic in March 2020, with
3,883,098 confirmed cases and 268,560
deaths as of May 7, 2020.
Initial publications describing SARS-
CoV-2 were mostly from China, with small
numbers of cancer patients. The National
Health Commission of China reported on
1,099 patients from 552 hospitals in main-
land China, noting a median age of 47
years, 58%male, and 24% had comorbid-
ities thatwere associatedwithmore severe
COVID-19 illness (Guan et al., 2020); only
0.9% of patients had cancer. The median
duration of hospitalization was 12 days,
5.0% required an admission to the inten-
sive care unit (ICU), and 1.4% died. The
most common presentation included fever742 Cancer Cell 37, June 8, 2020 ª 2020 Pubin 44%of patients at the time of admission,
increasing to 89% during hospitalization,
and cough (68%). Laboratory abnormal-
ities included lymphopenia (83%), throm-
bocytopenia (36%), and elevated C-reac-
tive protein (61%).
A report from Wuhan Jinyintan Hospital
identified 99 patients infected with SARS-
CoV-2. The median age was 55 years,
68% were male, and 51% had comorbid
disease, including cancer in only 1%of pa-
tients within the cohort (Chen et al., 2020).
The most common presenting symptoms
included fever (83%), cough (82%), and
dyspnea (31%). Laboratory abnormalities
included lymphopenia, anemia, and ab-
normalities in liver and kidney function
tests. Seventeen percent of patients devel-
oped acute respiratory distress syndrome
(ARDS), and 11% had died at the time of
publication. The first two deaths were in
patients with a long history of smoking.
A retrospective review of 138 patients
with COVID-19 from Zhongnan Hospital
of Wuhan University reported a medianlished by Elsevier Inc.age of 56 years, 54% were male, and
46% had comorbid disease, including
cancer in 7.2% of patients (Wang et al.,
2020). Common presenting symptoms
were fever (99%), fatigue (70%), cough
(59%), myalgia (35%), and dyspnea
(31%). Older age, hypertension, cardio-
vascular disease, and diabetes were risk
factors for ICU admission, while cancer
was not; however, this finding could be
biased due to treatment decisions and/
or restrictions in cancer patients. Treat-
ments included antiviral therapy (90%),
antibiotics (64%), and steroids (45%),
yet the impact of such therapies on sur-
vival was not reported. High D-Dimers
were identified as a negative prognostic
indicator. At the time of publication,
4.3% of patients had died.
Defining Impact of COVID-19 on
Thoracic Cancer Patients
While providing valuable data on this
lethal illness, the majority of these reports
are from single institutions, including
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wide spectrum of cancer diagnoses and
comorbid conditions. In a meta-analysis,
the overall pooled prevalence of cancer
in patients with COVID-19 was 2.0%
(Desai et al., 2020). Preliminary data did
not clarify whether cancer patients were
at higher risk of contracting the virus
compared to the general population, nor
did they elucidate risk factors for devel-
oping the most severe form of the dis-
ease. However, these data did suggest
the population most at risk of death from
COVID-19 was those affected by cardio-
vascular diseases, diabetes, and hyper-
tension as well as older age, male gender,
and obesity, which collectively corre-
sponds to a common prototype seen
with a co-existent lung cancer diagnosis.
Notably, a recent publication of 218 pa-
tients from Montefiore Health system in
the United States reported that cancer
patients with COVID-19 had a greater
risk of death compared to non-cancer pa-
tients, as well as a 55% (6/11) mortality
rate specific to lung cancer (Mehta et al.,
2020). Albeit with small numbers (n =
22), a publication from China suggested
that lung cancer patients had the sec-
ond-highest risk of developing severe
and critical symptoms, ICU admission,
and death behind hematological malig-
nancies (Dai et al., 2020).
Additionally, the specific impact of stage
of disease, oncologic therapeutic strategy,
and concomitant therapy on the severity
of COVID-19 could not be addressed in
these earlier reports, due to small patient
numbers and heterogeneity of the cohort.
One publication noted that the use of cor-
ticosteroids, which are frequently adminis-
tered to thoracic cancer patients during
treatment and for symptom management,
may worsen the sequelae of ARDS in pa-
tients with COVID-19 (Russell et al.,
2020). Markedly increased hypercoagula-
ble profiles due to hyperfibrinogenemia
were reported in a series of patients with
COVID-19 admitted to the ICU for ARDS,
leading to recommendations regarding
prophylactic anticoagulation in patients
admitted to hospital with COVID-19 (Ra-
nucci et al., 2020). As both cancer as a dis-
ease and cancer treatments are often
associated with a hypercoagulable state,
it is imperative to understand how a cancer
diagnosis along with concomitant thera-
pies and existing co-morbidities affects
outcomes in COVID-19 patients.Many societies have provided treatment
recommendations for patients with malig-
nancies during this pandemic, thereby re-
visiting our standards of care for cancer
patients and allowing for a better risk/
benefit ratio. Many hospitals underwent
radical reorganization, including imple-
menting telemedicine to minimize hospital
visits, identified as a contamination risk in
this community (Yu et al., 2020). A series
of questions started to emerge among
members of the thoracic community: para-
mount was how to balance the risk of
SARS-CoV-2 infection with the potential
risk of delaying cancer care, whether we
should treat patients according to the cur-
rent guidelines or by adapting care, and
determining the outcome of COVID-19 on
patients with thoracic cancers.
About the Consortium
TERAVOLT is the first global registry aimed
at understanding the impact of COVID-19
infection on patients with thoracic malig-
nancies, including patients with non-small
cell lung cancer (NSCLC), small cell lung
cancer (SCLC), mesothelioma, thymic
epithelial tumors, and carcinoid/neuroen-
docrine tumors of thoracic origin. The
goals of TERAVOLT are to (1) determine
in patients with thoracic malignancies
who develop COVID-19 the demographic,
comorbidities, and anticancer therapies
that place these patients most at risk for
hospitalization and death; (2) determine
the clinical picture of patients with thoracic
malignancies infected by SARS-CoV-2, a
diagnosis made more difficult when the
presentation of the illness is so similar to
the daily symptoms endured by many of
our patients; (3) provide practitioners with
real-time data on therapies that may
impact survival to COVID-19; and (4) eval-
uate long-term impacts on care and the
delay in care to patients with both curable
and incurable thoracic malignancies.
The consortium was founded on March
15, 2020, with a final steering committee
and live registry available less than a
week later (Figure 1A). The steering com-
mittee includes investigators from multi-
ple academic centers and with different
backgrounds (including thoracic malig-
nancy experts, statisticians, epidemiolo-
gists, and computational biologists), all
of whom are authors on this Commentary.
By May 7, 2020, participation extended to
both academic and community clinicians
from 185 institutions and 28 countries(Figure 1B), with over 400 cases entered
within the first 6 weeks. Participation in
the consortium is voluntary, but data-
base access requires approval from the
institution’s ethics committee. Case eligi-
bility criteria include any patient with
thoracic cancer who has a laboratory-
confirmed COVID-19 infection or sus-
pected infection due to symptoms (fever
>37.5C, decreased oximeter saturation
R5%, cough, diarrhea, otitis, dysgeusia,
myalgia, arthralgia, conjunctivitis, and rhi-
norrhea) and close contact with a patient
with a confirmed COVID-19 infection, or
with lung-imaging features consistent
with coronavirus pneumonia.
TERAVOLT collects the following data:
(1) baseline demographics including age,
smoking habits, sex/gender, and country
of origin; (2) patient’s baseline character-
istics, including co-morbidities and
concomitant therapies; (3) patient’s can-
cer diagnosis, stage, and current and
previous therapies, including chemo-
therapy, immunotherapy, targeted ther-
apy, surgery, and radiation; (4) patient’s
COVID-19 illness, including symptoms,
laboratory values, imaging, and treat-
ment measures (e.g., anticoagulation,
antibiotics, and antiviral therapy), either
as an outpatient or during the hospital
admission; and (5) outcome from
COVID-19 infection including intensive
care admission, prolonged hospitaliza-
tion, or death. These collected measures
are being analyzed to provide clinicians
with guidance on patient care in real
time. Additionally, timing of cancer ther-
apy relative to their COVID-19 diagnosis,
as well as anticancer therapy interrup-
tions following recovery, is also being
collected to determine the impact this
pandemic will have on the outcomes of
patients with thoracic malignancies.
TERAVOLT is utilizing REDCap, a
secure web platform for building and man-
aging online databases and surveys (Harris
et al., 2019). REDCap was developed spe-
cifically around HIPAA-Security guidelines
with servers housed in a local data center
at Vanderbilt University Medical Center
(VUMC), and all web-based information
transmission is encrypted. TERAVOLT sur-
vey and database maintenance and data
distribution are coordinated at VUMC,
and data analysis and interpretation are
performed jointly within the consortium. A
unique feature of this REDCap platform is
the ease of adapting the survey questionsCancer Cell 37, June 8, 2020 743
Figure 1. Consortium Development Timeline and Global Participation as of May 7, 2020
(A) TERAVOLT was rapidly conceived and executed, with over 400 patients entered into the database
within 6 weeks of being active.
(B) TERAVOLT includes participation from 28 countries across the world.
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llbased on the evolution of this pandemic,
allowing for additional measures to be
collected as our understanding of the virus
expands .
Harnessing the Power of a
Community
The rapid development and approval of
the TERAVOLT database highlights the
impact of this novel virus on the global
population. Fundamental to the data-
base’s success was the endorsement of
scientific societies, in particular Interna-
tional Association for the Study of Lung
Cancer (IASLC), European Society of
Medical Oncology (ESMO), European
Thoracic Oncology Platform (ETOP),
and European Respiratory Society
(ERS), which disseminated information
regarding the importance of this con-744 Cancer Cell 37, June 8, 2020sortium, along with a collaborative and
collegial steering committee. The first
data were presented just over a month
after the consortium was formed, indi-
cating a higher-than-expected mortality
(33%) in the first 200 patients with data
entered. The longitudinal nature of the
consortium and registry will allow us to
answer important questions on whether
mortality was due to the severity of
COVID-19 or to a patient’s underlying
cancer diagnosis, or rather due to deci-
sive factors from patients, physicians,
or institutions. TERAVOLT is also part-
nering with global advocacy groups to
develop patient-specific surveys that
will collect data globally on the cancer
patient’s perspective on the pandemic
and on their illness. We envision that
data from patient surveys can becombined with data from clinical regis-
tries in order to develop personalized
treatment options that consider the
patient’s perspective along with clinically
reasoned decisions. For more informa-
tion on TERAVOLT, please visit http://
teravolt-consortium.org/.ACKNOWLEDGMENTS
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